We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.90 | 2.80 | 3.00 | 2.90 | 2.90 | 2.90 | 671,838 | 08:00:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 13.09M | -33.29M | -0.0320 | -0.91 | 30.21M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/12/2024 07:24 | PATT it's more than 12.5 percentUnder the terms of the deal, Shield will receive an immediate £11 million upfront payment and is also in line to receive up to 4.5 million euros in short-term development milestones and up to 50 million euros in sales milestones..In addition, Shield will bank tiered royalties ranging from 25% to 40% of net sales of Feraccru..Those sales milestone were obviously set at stupid high amounts because none have come in. But it's 25-40 percent of Norgine sales. Nice to see this progress in UK and hope Germany is doing the same | skcots48 | |
22/12/2024 02:08 | Watch and learn. PURCHASEATTHETOP/ROB | antonagis | |
21/12/2024 19:25 | UK prescriptions rose to a record £115,344 in October 24 as compared to £60,923 in Oct 23 STX only get around 12% of that but the trend of sales is very encouraging. | purchaseatthetop | |
21/12/2024 16:13 | Antonagis, your posts are like a broken record stuck on the world's most boring tune. If repetition was an art form, you'd be Picasso... but of pointless drivel. | zeus19 | |
21/12/2024 11:06 | Ken Finn. Head of recruitment. Stated about California new sales jobs… “Great Opportunity in an expanded market” | purchaseatthetop | |
21/12/2024 05:16 | R95055etc. I don’t expect any data till around 22/1/25 now with Q4 24 trading update. They did t seem concerned about getting the extra £1m from the retail book offer as that deadline has passed. | purchaseatthetop | |
20/12/2024 21:12 | When is the Nov sales results? | r9505571 | |
20/12/2024 14:44 | They might get lucky with some large Dec orders before the break .But it's all speculation so we need hard numbers and to beat 31.5m | skcots48 | |
20/12/2024 10:32 | Best1467. I agree that it is very sensible to assume slight underperformance and see if that still works. Given they got $225 in October and $192 in Aug snd Sept, it seems very conservative to model $200 in Q4. In which case they need 50k prescriptions which is about the standard 7k rise a quarter. | purchaseatthetop | |
20/12/2024 09:43 | You keep quoting $220 that was average in October it’s not guaranteed across the full quarter let’s wait and see .I will be happy with anything above 192 across the Q4 | best1467 | |
20/12/2024 07:51 | Skcots. They did $20m in the first nine months of 2024. They have $1.5m of other royalties and milestone payments in Q4. That means they need $10m in Q4 from US product sales At $220 a pop that is 45,450 sales and they did 43k in Q3. So the rise would have to be tiny to miss the target. Of course they are not just going to beat the target. They are going $1m beyond it I think. | purchaseatthetop | |
20/12/2024 07:48 | AOP own nearly 60 percent of this company So the listing of STX Is 40 percent ownership of sales. The above is to make it look simple On the very intricate ownership and rights of STX Management are basically diluting STX shareholders to oblivion To the point of AOP taking full ownership | washingmachine | |
20/12/2024 07:42 | They have a vote to pass a subscription that without winning they run out of money in 6 months and they aren't guaranteed 31.5m, all they told us was that they were on track in October .So yes uncertainty and why I responded to your post about it powering up | skcots48 | |
20/12/2024 07:22 | Al Cap .. there are certain crimes that most people find unforgivable. Patt is a poisonous human, no escaping that reality | dplewis1 | |
20/12/2024 07:20 | I am not so sure about uncertainty. We can be pretty sure they have hit $31m in 2024 with nearly $12m in Q4 with average Rx about $220 plus the new recruiting suggests prescription growth is strong. 2025 is going to be very interesting. | purchaseatthetop | |
20/12/2024 07:13 | Sorry poor choice of word. Uncertainty | skcots48 | |
20/12/2024 01:42 | PURCHASEATTHETOP/RIC | antonagis | |
19/12/2024 23:39 | Skcots are you saying that AOP's new holding at 3p is an overhang? You expect them to dump their $10m new holding at 2.5p having just invested at 3p? (smacks own head) | cyberbub | |
19/12/2024 20:59 | Give the fella a break ffsLet he who is free of sin cast the first stone | alancapone | |
19/12/2024 12:26 | Skcots. Quite rightly nobody really trusts anything the BoD says because history is so bad! However the share price dropped heavily end Oct when they showed a drop in Rx from $170 to $167 or something like that. This was only due to the rogue July data. Since then every month sbove $200 which is quite amazing. Finally they are delivering but nobody quite believes it! | purchaseatthetop |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions